Avita Medical (NASDAQ:RCEL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Avita Medical (NASDAQ:RCEL) posted its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, FiscalAI reports. The company had revenue of $26.11 million during the quarter, compared to analyst estimates of $22.35 million.

Here are the key takeaways from Avita Medical’s conference call:

• AVITA reported Q3 revenue of $26.1 million, up 53% year over year and 20% sequentially, led by RECELL. It raised 2026 revenue guidance for the second consecutive quarter to $92 million–$94 million and reaffirmed its goal of cash flow breakeven in Q4.
• Cash use fell to approximately $600,000 from $3.2 million in Q2, while gross margin rose to 84% and operating expenses stayed flat sequentially. AVITA also received the remaining $10 million available under its credit facility, and management said substantial doubt about the company’s ability to continue as a going concern had been alleviated.
• U.S. RECELL revenue increased about 20% sequentially, with unit volume up approximately 21%; management attributed most of the growth to its commercial strategy, while estimating roughly $1 million of Q3 revenue came from seasonal burn activity. A simpler national Medicare reimbursement framework for RECELL procedures is scheduled to take effect in January 2027.
• Management estimated that Q3 benefited by about $1 million from seasonality, and its Q4 revenue outlook of $24.9 million–$26.9 million implies roughly flat revenue at the midpoint versus Q3. Cohealyx revenue grew 21% sequentially, while PermeaDerm was essentially flat; management said adoption and repeat use for the newer products are still developing.

Avita Medical Price Performance

Shares of RCEL traded up $0.91 during trading hours on Friday, hitting $16.59. 1,137,548 shares of the stock were exchanged, compared to its average volume of 423,488. Avita Medical has a fifty-two week low of $3.22 and a fifty-two week high of $18.07. The business has a 50-day moving average of $12.77 and a 200-day moving average of $6.85. The firm has a market capitalization of $510.64 million, a P/E ratio of -14.06 and a beta of 2.03.

Key Avita Medical News

Here are the key news stories impacting Avita Medical this week:

• Positive Sentiment: Raised revenue outlook: Avita lifted its full-year 2026 revenue guidance, signaling improved expectations for growth. AVITA Medical Raises Revenue Guidance
• Positive Sentiment: Q3 beat estimates: The company reported revenue of $26.11 million, above the $22.35 million analyst consensus, and a loss of $0.20 per share, narrower than the expected $0.24 loss. Another report said revenue surged 53% year over year. AVITA Medical Reports Third Quarter Results Q3 Revenue Growth
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $15 to $21 and maintained a Buy rating, reflecting greater potential upside in its assessment. BTIG Raises Price Target
• Positive Sentiment: Medicare billing changes: A national physician payment framework and simplified billing codes for RECELL procedures are scheduled for 2027. These changes could ease billing complexity and support broader procedure adoption. Medicare Payment Framework and Billing Codes

Analysts Set New Price Targets

RCEL has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Lake Street Capital increased their price target on Avita Medical from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, August 28th. TD Cowen restated a “buy” rating on shares of Avita Medical in a research report on Tuesday. BTIG Research raised their price objective on Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen raised Avita Medical from a “sell” rating to a “hold” rating in a research note on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Avita Medical has a consensus rating of “Moderate Buy” and an average price target of $13.40.

About Avita Medical

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.